{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T04:21:02Z","timestamp":1787458862463,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04232-9","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:22:34Z","timestamp":1773058954000},"page":"3850-3861","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Utilization of MRI-based radiomics nomogram for predicting HER2-zero, -low, and -overexpression breast cancer"],"prefix":"10.1007","volume":"28","author":[{"given":"Licui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoya","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5830-1493","authenticated-orcid":false,"given":"Ying","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"issue":"3","key":"4232_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"4232_CR2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-12-0452","author":"JD Wulfkuhle","year":"2012","unstructured":"Wulfkuhle JD, Berg D, Wolff C, Langer R, Tran K, Illi J, et al. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res. 2012. https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-0452.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4232_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22(2):101\u201326.","journal-title":"Nat Rev Drug Discov"},{"key":"4232_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1914510","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/nejmoa1914510.","journal-title":"N Engl J Med"},{"issue":"8","key":"4232_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","volume":"34","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol: official journal of the European Society for Medical Oncology. 2023;34(8):645.","journal-title":"Ann Oncol: official journal of the European Society for Medical Oncology"},{"key":"4232_CR6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02488","author":"P Tarantino","year":"2020","unstructured":"Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020. https:\/\/doi.org\/10.1200\/JCO.19.02488.","journal-title":"J Clin Oncol"},{"key":"4232_CR7","doi-asserted-by":"publisher","first-page":"1100332","DOI":"10.3389\/fonc.2023.1100332","volume":"13","author":"T Wei","year":"2023","unstructured":"Wei T, Wang D, Gao S, Wang X, Yue J, Kang Y, et al. Clinicopathologic characteristics and prognostic significance of HER2-low expression in patients with early breast cancer: a systematic review and meta-analysis. Front Oncol. 2023;13:1100332.","journal-title":"Front Oncol"},{"issue":"1","key":"4232_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13058-023-01639-y","volume":"25","author":"XE Hu","year":"2023","unstructured":"Hu XE, Yang P, Chen S, Wei G, Yuan L, Yang Z, et al. Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low. Breast Cancer Res: BCR. 2023;25(1):34.","journal-title":"Breast Cancer Res: BCR"},{"key":"4232_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejca.2022.09.017","volume":"176","author":"A de Nonneville","year":"2022","unstructured":"de Nonneville A, Houvenaeghel G, Cohen M, Sabiani L, Bannier M, Viret F, et al. Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers. Eur J Cancer. 2022;176:181\u20138.","journal-title":"Eur J Cancer"},{"key":"4232_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-10641-7","author":"S Zheng","year":"2024","unstructured":"Zheng S, Yang Z, Du G, Zhang Y, Jiang C, Xu T, et al. Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics. Eur Radiol. 2024. https:\/\/doi.org\/10.1007\/s00330-024-10641-7.","journal-title":"Eur Radiol"},{"issue":"1","key":"4232_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04076-9","volume":"21","author":"J Jin","year":"2023","unstructured":"Jin J, Li B, Cao J, Li T, Zhang J, Cao J, et al. Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer. J Transl Med. 2023;21(1):360.","journal-title":"J Transl Med"},{"issue":"5","key":"4232_CR12","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1200\/JCO.19.01455","volume":"38","author":"L Fehrenbacher","year":"2020","unstructured":"Fehrenbacher L, Cecchini RS, Geyer JCE, et al. NSABP B-47\/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2+. J Clin Oncol. 2020;38(5):444\u201353.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4232_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"key":"4232_CR14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02318","author":"S Modi","year":"2020","unstructured":"Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol. 2020. https:\/\/doi.org\/10.1200\/jco.19.02318.","journal-title":"J Clin Oncol"},{"key":"4232_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.847835","volume":"9","author":"J Yu","year":"2022","unstructured":"Yu J, Fang T, Yun C, Liu X, Cai X. Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers. Front Mol Biosci. 2022;9:847835.","journal-title":"Front Mol Biosci"},{"issue":"7","key":"4232_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071837","volume":"14","author":"AS Kazerouni","year":"2022","unstructured":"Kazerouni AS, Hormuth DA 2nd, Davis T, Bloom MJ, Mounho S, Rahman G, et al. Quantifying tumor heterogeneity via MRI habitats to characterize microenvironmental alterations in HER2+ breast cancer. Cancers. 2022;14(7):1837.","journal-title":"Cancers"},{"issue":"12","key":"4232_CR17","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol: official journal of the American Society of Clinical Oncology. 2020;38(12):1346\u201366.","journal-title":"J Clin Oncol: official journal of the American Society of Clinical Oncology"},{"issue":"8","key":"4232_CR18","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Th\u00fcrlimann B, Senn HJ. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the st. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol: official journal of the European Society for Medical Oncology. 2011;22(8):1736\u201347.","journal-title":"Ann Oncol: official journal of the European Society for Medical Oncology"},{"issue":"2","key":"4232_CR19","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1148\/radiol.2020191145","volume":"295","author":"A Zwanenburg","year":"2020","unstructured":"Zwanenburg A, Valli\u00e8res M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295(2):328\u201338.","journal-title":"Radiology"},{"issue":"1","key":"4232_CR20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13058-019-1199-8","volume":"21","author":"M Fan","year":"2019","unstructured":"Fan M, Xia P, Liu B, Zhang L, Wang Y, Gao X, et al. Tumour heterogeneity revealed by unsupervised decomposition of dynamic contrast-enhanced magnetic resonance imaging is associated with underlying gene expression patterns and poor survival in breast cancer patients. Breast Cancer Res: BCR. 2019;21(1):112.","journal-title":"Breast Cancer Res: BCR"},{"issue":"5","key":"4232_CR21","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1158\/1078-0432.CCR-0951-3","volume":"10","author":"GE Konecny","year":"2004","unstructured":"Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, et al. Association between HER-2\/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res. 2004;10(5):1706\u201316.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4232_CR22","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00330-023-09990-6","volume":"34","author":"Y Guo","year":"2024","unstructured":"Guo Y, Xie X, Tang W, Chen S, Wang M, Fan Y, et al. Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer. Eur Radiol. 2024;34(2):899\u2013913.","journal-title":"Eur Radiol"},{"issue":"1","key":"4232_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-025-00880-2","volume":"25","author":"X Hou","year":"2025","unstructured":"Hou X, Chen K, Luo H, Xu W, Li X. Identification of HER2-over-expression, HER2-low-expression, and HER2-zero-expression statuses in breast cancer based on 18F-FDG PET\/CT radiomics. Cancer Imaging. 2025;25(1):62.","journal-title":"Cancer Imaging"},{"issue":"9","key":"4232_CR24","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1007\/s00330-024-10641-7","volume":"34","author":"S Zheng","year":"2024","unstructured":"Zheng S, Yang Z, Du G, Zhang Y, Jiang C, Xu T, et al. Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics. Eur Radiol. 2024;34(9):6132\u201344.","journal-title":"Eur Radiol"},{"issue":"2","key":"4232_CR25","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222646","volume":"308","author":"T Ramtohul","year":"2023","unstructured":"Ramtohul T, Djerroudi L, Lissavalid E, Nhy C, Redon L, Ikni L, et al. Multiparametric MRI and radiomics for the prediction of HER2-zero, -low, and -positive breast cancers. Radiology. 2023;308(2):e222646.","journal-title":"Radiology"},{"issue":"4","key":"4232_CR26","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.23.30603","volume":"222","author":"Y Peng","year":"2024","unstructured":"Peng Y, Zhang X, Qiu Y, Li B, Yang Z, Huang J, et al. Development and validation of MRI radiomics models to differentiate HER2-zero, -low, and -positive breast cancer. Am J Roentgenol. 2024;222(4):e2330603.","journal-title":"Am J Roentgenol"},{"issue":"5","key":"4232_CR27","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/jmri.28628","volume":"58","author":"X Bian","year":"2023","unstructured":"Bian X, Du S, Yue Z, Gao S, Zhao R, Huang G, et al. Potential antihuman epidermal growth factor receptor 2 target therapy beneficiaries: the role of MRI \u2010based radiomics in distinguishing human epidermal growth factor receptor 2\u2010low status of breast cancer. J Magn Reson Imaging. 2023;58(5):1603\u201314.","journal-title":"J Magn Reson Imaging"},{"key":"4232_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2020.05.040","author":"J Zhou","year":"2021","unstructured":"Zhou J, Tan H, Li W, Liu Z, Wu Y, Bai Y, et al. Radiomics signatures based on multiparametric MRI for the preoperative prediction of the HER2 status of patients with breast cancer. Acad Radiol. 2021. https:\/\/doi.org\/10.1016\/j.acra.2020.05.040.","journal-title":"Acad Radiol"},{"key":"4232_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1531553","volume":"15","author":"X Li","year":"2025","unstructured":"Li X, Fang J, Wang F, Zhang L, Jiang X, Mao X. Prediction of HER2 expression in breast cancer patients based on multi-parametric MRI intratumoral and peritumoral radiomics features combined with clinical and imaging indicators. Front Oncol. 2025;15:1531553.","journal-title":"Front Oncol"},{"key":"4232_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.mri.2025.110434","volume":"122","author":"M Cao","year":"2025","unstructured":"Cao M, Liu X, Yang A, Xu Y, Zhang Q, Cao Y. Prediction of HER-2 expression status in breast cancer based on multi-parameter MRI intratumoral and peritumoral radiomics. Magn Reson Imaging. 2025;122:110434.","journal-title":"Magn Reson Imaging"},{"issue":"3 Pt 2","key":"4232_CR31","doi-asserted-by":"publisher","first-page":"1013s","DOI":"10.1158\/1078-0432.CCR-05-2128","volume":"12","author":"HJ Kim","year":"2006","unstructured":"Kim HJ, Cui X, Hilsenbeck SG, Lee AV. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res. 2006;12(3 Pt 2):1013s\u20138s.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4232_CR32","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.7314\/APJCP.2016.17.3.1015","volume":"17","author":"M Payandeh","year":"2016","unstructured":"Payandeh M, Shahriari-Ahmadi A, Sadeghi M, Sadeghi E. Correlations between HER2 expression and other prognostic factors in breast cancer: inverse relations with the Ki-67 index and P53 status. Asian Pac J Cancer Prev. 2016;17(3):1015\u20138.","journal-title":"Asian Pac J Cancer Prev"},{"key":"4232_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.922185","volume":"12","author":"C Fang","year":"2022","unstructured":"Fang C, Zhang J, Li J, Shang H, Li K, Jiao T, et al. Clinical-radiomics nomogram for identifying HER2 status in patients with breast cancer: a multicenter study. Front Oncol. 2022;12:922185.","journal-title":"Front Oncol"},{"issue":"4","key":"4232_CR34","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jamaoncol.2022.7476","volume":"9","author":"DS Peiffer","year":"2023","unstructured":"Peiffer DS, Zhao F, Chen N, Hahn OM, Nanda R, Olopade OI, et al. Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the national cancer database. JAMA Oncol. 2023;9(4):500\u201310.","journal-title":"JAMA Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04232-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04232-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04232-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T03:22:05Z","timestamp":1787455325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04232-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["4232"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04232-9","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the institutional ethics committee, and the informed consent was waived owing to the retrospective design of the research. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}